semaglutide malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF GLP-1 Drugs & Malnutrition: Why
Description
Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.
With antiamyloid antibodies Leqembi (lecanemab) and Kisunla (donanemab) now FDAapproved for early Alzheimers, attention is turning to combination strategies that address multiple disease pathways
Learn when side effects improve and effective management strategies
Medical weight loss, GLP-1 therapy & metabolism support in Bristol VA
